CARB-X is a non-profit partnership
CARB-X is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the United States Department of Health and Human Services, the Wellcome Trust in the United Kingdom, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). CARB-X is investing up to US$480 million from 2016-2022 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics to address drug-resistant bacteria. CARB-X is led by Boston University and is headquartered in the Boston University School of Law.
Business, technical and scientific support for CARB-X-funded product developers is provided by CARB-X’s Global Accelerator Network.